Latest Migraine Stories

SICHUAN, China, July 17, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI) announced today the successful development of a revolutionary TCM migraine medication called Toufeng Migraine tablet. The medication has demonstrated an effective rate of 96.5% in clinical observations. The new product was developed utilizing the company's Dahurian Angelica (DAR) as one it's key ingredients. According to the company's forecast, the world's major pharmaceutical...

redOrbit Staff & Wire Reports - Your Universe Online Six months after Excedrin was pulled from store shelves as part of a recall, migraine patients face a difficult dilemma -- try to find an alternative and nearly-as-effective method of treatment, or pay exorbitant prices online for a product that they know can help alleviate the pain caused by their severe headaches. According to Kim Carollo of ABC News, Excedrin was pulled on January 8 -- along with the stimulant No-Doz, the oral...

redOrbit Staff & Wire Reports - Your Universe Online Usually when a man watches pornography, it causes headaches for the significant other in his life, but not in the case of a healthy, single, 24-year-old software engineer from India, who researchers have discovered suffers from debilitating cranial pain while watching sexually-charged video footage. According to Claire Bates of the Daily Mail, neurologists in New Dehli treated the man, who experienced "exploding pain across his...

Researchers find a simple way of avoiding dangerous side effects The commonly-used epilepsy drug, valproic acid (VPA), can have a highly beneficial effect on some babies born with spinal muscular atrophy (SMA), the number one genetic killer during early infancy. But in about two-thirds of such cases it is either damaging or simply has no effect. Now, for the first time, researchers have found a way to identify which patients are likely to respond well to VPA prior to starting treatment....

MOUNTAIN VIEW, Calif., June 25, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company completed an End-of-Review meeting with the United States Food and Drug Administration (FDA) for its New Drug Application (NDA) for LEVADEX® (dihydroergotamine) inhalation aerosol. MAP Pharmaceuticals requested the End-of-Review meeting following receipt of a Complete Response letter (CRL) on March 26, 2012. The Company is seeking approval of LEVADEX for...

MOUNTAIN VIEW, Calif., June 21, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present data on LEVADEX® (formerly MAP0004), an orally inhaled investigational drug for the acute treatment of migraine, at the 54th Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, CA, June 21-24, 2012. The Company will present five poster presentations: Acute Inhalation Safety of MAP0004: Studies in Healthy...

Earlier detection, prompt and appropriate treatment, and prevention can lessen neurological, physical and psychological consequences of severe head trauma in America's soldiers and teen athletes The impact of traumatic injuries to the brain – whether sustained in combat or on the playing fields of America's schools – is a major topic for international migraine specialists the week of June 18 as they gather in Los Angeles for the 54th Annual Scientific Sessions of the American Headache...

SICHUAN, China, June 19, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that it has signed a new sales letter of intent (LOI) for this year for its proprietary Yishen Capsule valued at 25 million RMB; approximately $4 million USD. The LOI was signed with Pengxi Huitong Pharmaceutical Ltd. for the purchase of a total of 2,200,000 packs for delivery thru 2012. YiShen Capsules are a proprietary product of CHRI used to treat fatigue by...

Meniere's Disease & Trigeminal Neuralgia Breakthrough; A Story of Survival! Learn about important traditional & complementary alternatives to one-sided neurological problems like Meniere's Disease, Trigeminal Neuralgia, Glossopharyngeal Neuralgia, Bell's Palsy, Parkinson's Disease & Migraines. Grand Rapids, MI (PRWEB) June 17, 2012 The featured speaker at this years Meniere's Disease Research Institute's Work Shop is Dr. Michael T. Burcon, world's leading...

SAN JOSE, Calif., June 12, 2012 /PRNewswire/ -- US patent 8,197,858 issued on June 12, 2012 discloses a previously unknown pathogenesis underlying seizures / epilepsy and migraines and provides novel treatment options for the 50 million seizure patients and 300 million migraine sufferers worldwide. "We scientifically validated that triggers such as drops in estrogen or testosterone or increases in prostaglandin or Vitamin D synthesis all boost release of calcium ions from bone. We...